Gleneagle Gold Ltd (ASX:GLN) shareholders recently approved the acquisition of Zelda Therapeutics Pty Ltd, a biotechnology company focused on medical cannabis therapies.
Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.
This week Dr. Stewart Washer, executive director, joined the Proactive Spotlight CEO Investor Session in Sydney, outlining the company strategy to investors.
ACCESS THE FULL PRESENTATION HERE
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.